clofibrate has been researched along with Innate Inflammatory Response in 12 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 7.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| "Daily intramuscular injections of clofibrate begun 6h before the initiation of inflammation induced by the subcutaneous injection of turpentine exerted a differential, dose-dependent inhibition of the anticipated acute-phase globulin response." | 7.66 | Differential effect of clofibrate on inflammation-induced alterations in plasma proteins in the rat. ( Abeles, FB; Bostian, KA; Fowler, JP; Hauer, EC; Powanda, MC, 1979) |
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 5.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| "Oxidative stress and inflammation have been considered the main factors in the liver injury of clofibrate (CF)." | 4.02 | The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity. ( Cheng, L; Guo, M; He, Y; Jiang, H; Liu, J; Ren, C; Shi, Y; Sun, M; Wang, B; Wang, W; Wang, X; Xie, Y; Xu, X, 2021) |
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 3.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| "Daily intramuscular injections of clofibrate begun 6h before the initiation of inflammation induced by the subcutaneous injection of turpentine exerted a differential, dose-dependent inhibition of the anticipated acute-phase globulin response." | 3.66 | Differential effect of clofibrate on inflammation-induced alterations in plasma proteins in the rat. ( Abeles, FB; Bostian, KA; Fowler, JP; Hauer, EC; Powanda, MC, 1979) |
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 1.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Xie, Y | 1 |
| Liu, J | 1 |
| Shi, Y | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Wang, W | 1 |
| Sun, M | 1 |
| Xu, X | 1 |
| Jiang, H | 1 |
| Guo, M | 1 |
| He, Y | 1 |
| Ren, C | 1 |
| Cheng, L | 1 |
| Sánchez-Aguilar, M | 2 |
| Ibarra-Lara, L | 2 |
| Cano-Martínez, A | 1 |
| Soria-Castro, E | 2 |
| Castrejón-Téllez, V | 1 |
| Pavón, N | 2 |
| Osorio-Yáñez, C | 1 |
| Díaz-Díaz, E | 1 |
| Rubio-Ruíz, ME | 1 |
| Oyagbemi, AA | 1 |
| Adebiyi, OE | 1 |
| Adigun, KO | 1 |
| Ogunpolu, BS | 1 |
| Falayi, OO | 1 |
| Hassan, FO | 1 |
| Folarin, OR | 1 |
| Adebayo, AK | 1 |
| Adejumobi, OA | 1 |
| Asenuga, ER | 1 |
| Ola-Davies, OE | 1 |
| Omobowale, TO | 1 |
| Olopade, JO | 1 |
| Saba, AB | 1 |
| Adedapo, AA | 1 |
| Nkadimeng, SM | 1 |
| McGaw, LJ | 1 |
| Oguntibeju, OO | 1 |
| Yakubu, MA | 1 |
| Vargas-Barrón, J | 1 |
| Roldán, FJ | 1 |
| Torres-Narváez, JC | 1 |
| Cervantes-Pérez, LG | 1 |
| Pastelín-Hernández, G | 1 |
| Sánchez-Mendoza, A | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Baldo, BA | 1 |
| Powanda, MC | 1 |
| Abeles, FB | 1 |
| Bostian, KA | 1 |
| Fowler, JP | 1 |
| Hauer, EC | 1 |
| Verstraete, M | 1 |
| Fearnley, GR | 1 |
| Vargaftig, BB | 1 |
| Zirinis, P | 1 |
3 reviews available for clofibrate and Innate Inflammatory Response
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
The position of long-term stimulation of the endogenous fibrinolytic system: present achievements and clinical perspectives.
Topics: Adrenocorticotropic Hormone; Anabolic Agents; Androgens; Clofibrate; Coronary Disease; Deamino Argin | 1975 |
Fibrinolysis.
Topics: Aminocaproates; Anabolic Agents; Androgens; Antifibrinolytic Agents; Arterial Occlusive Diseases; Bl | 1973 |
9 other studies available for clofibrate and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Benzodioxoles; Clofibric Acid; Dose- | 2021 |
PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response.
Topics: Animals; Arrhythmias, Cardiac; Atrial Natriuretic Factor; Clofibrate; Inflammation; Ischemia; Metabo | 2023 |
Clofibrate, a PPAR-α agonist, abrogates sodium fluoride-induced neuroinflammation, oxidative stress, and motor incoordination via modulation of GFAP/Iba-1/anti-calbindin signaling pathways.
Topics: Animals; Ataxia; Biomarkers; Calbindins; Calcium-Binding Proteins; Clofibrate; Fluorides; Glial Fibr | 2020 |
Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model.
Topics: Animals; Clofibrate; Cytokines; Disease Models, Animal; Hypolipidemic Agents; Inflammation; Inflamma | 2019 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Additional inhibitors of rat serum acute phase alpha 2-macroglobulin levels. Effect of 6-mercaptopurine and some lipoxygenase and cyclo-oxygenase inhibitors.
Topics: 5,8,11,14-Eicosatetraynoic Acid; alpha-Macroglobulins; Animals; Clofibrate; Cyclooxygenase Inhibitor | 1982 |
Differential effect of clofibrate on inflammation-induced alterations in plasma proteins in the rat.
Topics: alpha-Macroglobulins; Amino Acids; Animals; Blood Proteins; Clofibrate; Copper; Inflammation; Liver; | 1979 |
Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2.
Topics: Acetaminophen; Anti-Inflammatory Agents; Aorta; Arachidonic Acids; Aspirin; Biological Assay; Blood | 1973 |